#BIO22: De­cen­tral­ized tri­als

Zachary Bren­nan:

Hel­lo. Good morn­ing. I’m Zachary Bren­nan, se­nior ed­i­tor at End­points News. And thank you for join­ing us vir­tu­al­ly at BIO for our pan­el on de­cen­tral­ized tri­als. Join­ing me to­day, we have Ro­nan Brown, Se­nior Vice Pres­i­dent of IQVIA, Craig Lipset, founder of Clin­i­cal In­no­va­tion Part­ners, and Bari Kow­al, se­nior vice pres­i­dent of Re­gen­eron. I’m ex­cit­ed for to­day’s dis­cus­sion and I’m sure you are too, but be­fore we get in­to it, we have a brief word from Vice Pres­i­dent Matt Blume with to­day’s spon­sor, Catal­ent.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN